Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Teck Resources (TECK) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance

Teck ResourcesTrade
State Street SPDR S&P Biotech ETFTrade

Price performance (Past 24H)

Key statistics

Teck Resources vs State Street SPDR S&P Biotech ETF — how do they compare? Teck Resources trades at $70.2 (market cap $35.27B), while State Street SPDR S&P Biotech ETF trades at $159.9. The key difference: Teck Resources pays a 0.49% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals.

TECKXBI
Market Cap
$35.27B
Sector
IndustrialsBroad Market / Factor
52-Week High
$71.97$169.55
52-Week Low
$38.23$93.43
Enterprise Value
$37.98B
Dividend Yield
0.49%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Teck Resources

No Aura AI signal available yet.

State Street SPDR S&P Biotech ETF

XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.

Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Teck Resources

Teck Resources is a mining company focused on producing metals and minerals, including copper and zinc. Its operations supply materials used in infrastructure, manufacturing, and energy-related industries.

Read more on TECK

About State Street SPDR S&P Biotech ETF

XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.

Read more on XBI